Mediar Therapeutics CEO Rahul Ballal (L) and CSO Paul Yaworsky
Lilly ventures into pulmonary fibrosis with startup Mediar
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis.
Lilly — one of the five large pharmas …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.